dc.contributor.author | Brogyányi, Tereza | |
dc.contributor.author | Kejík, Zdeněk | |
dc.contributor.author | Veselá, Kateřina | |
dc.contributor.author | Dytrych, Petr | |
dc.contributor.author | Hoskovec, David | |
dc.contributor.author | Masařík, Michal | |
dc.contributor.author | Babula, Petr | |
dc.contributor.author | Kaplánek, Robert | |
dc.contributor.author | Přibyl, Tomáš | |
dc.contributor.author | Zelenka, Jaroslav | |
dc.contributor.author | Ruml, Tomáš | |
dc.contributor.author | Vokurka, Martin | |
dc.contributor.author | Martásek, Pavel | |
dc.contributor.author | Jakubek, Milan | |
dc.date.accessioned | 2024-11-12T11:41:13Z | |
dc.date.available | 2024-11-12T11:41:13Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2690 | |
dc.description.abstract | Mitochondrial autophagy (mitophagy) is very important process for the maintenance of cellular homeostasis, functionality and survival. Its dysregulation is associated with high risk and progression numerous serious diseases (e.g., oncological, neurodegenerative and cardiovascular ones). Therefore, targeting mitophagy mechanisms is very hot topic in the biological and medicinal research. The interrelationships between the regulation of mitophagy and iron homeostasis are now becoming apparent. In short, mitochondria are central point for the regulation of iron homeostasis, but change in intracellular cheatable iron level can induce/repress mitophagy. In this review, relationships between iron homeostasis and mitophagy are thoroughly discussed and described. Also, therapeutic applicability of mitophagy chelators in the context of individual diseases is comprehensively and critically evaluated. | en |
dc.language.iso | en | |
dc.relation.url | https://doi.org/10.1016/j.biopha.2024.117407 | |
dc.rights | Creative Commons Uveďte původ 4.0 International | cs |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.title | Iron chelators as mitophagy agents: Potential and limitations | en |
dcterms.accessRights | openAccess | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/legalcode | |
dc.date.updated | 2024-11-12T11:41:13Z | |
dc.subject.keyword | Mitophagy | en |
dc.subject.keyword | Iron heomeostais | en |
dc.subject.keyword | Iron chelators | en |
dc.subject.keyword | Cancer | en |
dc.subject.keyword | Neurodegenerative diseases | en |
dc.subject.keyword | Cardiovascular diseases | en |
dc.subject.keyword | | en |
dc.identifier.eissn | 1950-6007 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5102 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5104 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5107 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//SVV260637 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//SVV260521 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/COOP/COOP | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM/LM/LM2023053 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/TA0/TN/TN02000109 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU22-08-00160 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407 | |
dc.date.embargoStartDate | 2024-11-12 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.1016/j.biopha.2024.117407 | |
dc.identifier.utWos | 001314505400001 | |
dc.identifier.eidScopus | 2-s2.0-85203549767 | |
dc.identifier.obd | 652962 | |
dc.identifier.pubmed | 39265234 | |
dc.subject.rivPrimary | 30000::30100 | |
dc.subject.rivSecondary | 10000::10600 | |
dcterms.isPartOf.name | Biomedicine & Pharmacotherapy | |
dcterms.isPartOf.issn | 0753-3322 | |
dcterms.isPartOf.journalYear | 2024 | |
dcterms.isPartOf.journalVolume | 179 | |
dcterms.isPartOf.journalIssue | October | |
uk.faculty.primaryId | 108 | |
uk.faculty.primaryName | 1. lékařská fakulta | cs |
uk.faculty.primaryName | First Faculty of Medicine | en |
uk.faculty.secondaryId | 53 | |
uk.faculty.secondaryName | Všeobecná fakultní nemocnice v Praze | cs |
uk.faculty.secondaryName | Všeobecná fakultní nemocnice v Praze | en |
uk.department.primaryId | 100025448551 | |
uk.department.primaryName | BIOCEV 1. lékařské fakulty | cs |
uk.department.primaryName | BIOCEV of the 1st Faculty of Medicine | en |
uk.department.secondaryId | 1522 | |
uk.department.secondaryId | 5000002594 | |
uk.department.secondaryId | 1496 | |
uk.department.secondaryId | 1508 | |
uk.department.secondaryId | 5000002603 | |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1. LF a VFN | cs |
uk.department.secondaryName | Department of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFN | en |
uk.department.secondaryName | I. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFN | cs |
uk.department.secondaryName | I. chirurgická klinika - břišní, hrudní a úrazová chirurgie 1.LF a VFN | en |
uk.department.secondaryName | Ústav patologické fyziologie 1. LF UK | cs |
uk.department.secondaryName | Institute of Pathological Physiology | en |
uk.department.secondaryName | I. chirurgická klinika – břišní, hrudní a úrazové chirurgie 1. LF UK a VFN | cs |
uk.department.secondaryName | 1st Department of Surgery – Department of Abdominal, Thoracic Surgery and Traumatology | en |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1.LF a VFN | cs |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1.LF a VFN | en |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::přehledový článek | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::summarizing article | en |
dc.type.obdHierarchyCode | 73::152::205 | en |
uk.displayTitle | Iron chelators as mitophagy agents: Potential and limitations | en |